CRESCENT BIOPHARMA, INC.

CBIO

CRESCENT BIOPHARMA, INC.

CBIO

Insider Sentiment (TTM):

Last Purchase:2025-12-04Last Sale:2026-06-22Shares Purchased (TTM):1,360,000Shares Sold (TTM):68,156

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:24,755,630Shares Outstanding:27,571,935Institutional Ownership Pct.:89.79%

Earnings Market Reaction:

Filing Date:2026-07-30Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Nonrelated Party	1	1	10	1	2	-	0	-	-	-	-	-
Related Party	1	1	10	1	2	-	0	15	-	-	-	-
Series Seed Convertible Preferred Stock	-	-	0	0	-20	20	0	0	-	-	-	-
Series A Preferred Stock	-	-	0	0	0	-	0	-	-	-	-	-
Assets
Assets Current
Other Assets	-	-	-	-	-	-	-	0	0	0	0	-
Cash And Cash Equivalents At Carrying Value	172	189	213	133	153	22	35	14	22	31	42	49
Cash	-	-	-	-	153	-	-	-	-	-	-	-
Accounts Receivable Net Current	0	0	18	-	-	-	0	-	-	-	-	-
Prepaid Expense And Other Assets Current	7	6	5	1	2	0	0	1	1	2	2	3
Assets Current	179	196	237	135	154	6	35	16	24	33	44	52
Prepaid Expense Noncurrent	-	-	-	-	-	-	-	-	-	0	1	0
Security Deposit	-	-	-	-	-	-	-	-	-	-	-	0
Property Plant And Equipment Net	1	1	1	1	0	-	0	-	-	-	-	0
Operating Lease Right Of Use Asset	1	1	1	2	2	-	0	-	0	1	1	1
Restricted Cash Noncurrent	0	0	0	0	0	-	0	-	-	-	-	-
Accrued Liabilities Current	-	-	16	-	-	3	2	3	3	4	5	5
Other Assets Noncurrent	1	1	1	1	1	-	1	-	-	-	-	-
Assets	183	199	240	138	157	6	36	16	24	34	45	53
Accounts Payable Current	-	-	-	-	-	0	0	1	1	1	1	0
Liabilities And Stockhold…
Liabilities Current
Stockholders Equity
Contract With Customer Liability Current	3	3	4	-	-	-	0	-	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	-	0	0	0	1	1	1
Liabilities Current	19	14	36	20	17	3	10	4	4	5	7	6
Liabilities Noncurrent
Operating Lease Liability Noncurrent	1	1	1	1	1	-	0	-	-	-	0	0
Liabilities	20	15	37	22	18	3	47	4	4	5	7	7
Stockholders Equity Inclu…
Preferred Stock Value	4	4	-	-	-	-	-	-	-	-	-	-
Temporary Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	379	375	371	192	190	500	2	498	497	496	495	494
Retained Earnings Accumulated Deficit	-220	-195	-172	-79	-55	-497	-18	-487	-477	-467	-456	-447
Stockholders Equity	163	184	203	117	139	-30	-15	0	20	29	38	47
Liabilities And Stockholders Equity	183	199	240	138	157	6	36	16	24	34	45	53
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	-	-	-	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	-	-	-	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	-	-	-	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	-	-	-	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	175	175	175	175	175	150	40	150	150	100	100	100
Common Stock Shares Issued	28	28	28	14	14	1	1	1	1	1	1	1
Shares Outstanding	28	28	28	14	14	1	1	1	1	1	1	1
Long Term Notes Payable	-	-	0	0	0	-	37	-	-	-	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.96%	-15.52%	-29.56%	-	-	-	-	-	-	-	-	-
2025	-20.83%	-33.79%	-50.00%	21.26%	4.03%	0.97%	14.89%	-5.73%	-2.29%	-11.74%	72.31%	61.70%
2024	-10.00%	-6.67%	-20.00%	-5.26%	-10.53%	-10.53%	-27.50%	-30.00%	-32.50%	-3.57%	-35.71%	-7.14%
2023	-	-	-	3.77%	-11.32%	-20.75%	17.78%	88.15%	120.74%	-39.31%	-90.57%	-91.82%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	9.66	13.78	6.56	6.63	9.21	2.29	3.62	3.62	5.48	6.28	6.41	8.14
Quick Ratio	9.26	13.33	6.41	6.56	9.12	2.15	3.62	3.33	5.14	5.91	6.11	7.73
Working Capital	160.47M	181.37M	200.58M	114.26M	137.48M	3.38M	25.19M	11.32M	19.50M	27.97M	36.96M	45.62M
Leverage & Debt
Debt to Equity	0.12	0.08	0.18	0.19	0.13	-0.09	-3.04	0.38	0.22	0.18	0.18	0.14
Interest Coverage TTM	-	-152.04	-69.85	-17.86	-9.61	-8.42	-10.25	-25.19	-23.18	-18.16	-16.53	-17.98
Debt Ratio	0.11	0.08	0.16	0.16	0.12	0.44	1.32	0.28	0.18	0.15	0.15	0.13
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Receivables Turnover TTM	-	-	0.00	-	-	-	-	-	-	-	-	-
Per Share Metrics
Diluted EPS TTM	-	-	-	-	-	-	-60.02	-50.46	-60.66	-57.77	-58.25	-59.15
Free Cash Flow Per Share TTM	-2.65	-2.56	-2.63	-3.73	-1.03	-10.28	-9.77	-11.85	-55.40	-52.45	-55.10	-54.70
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-16,214.73%	-15,701.35%	-	-	-	-	-	-	-	-	-	-
Net Profit Margin TTM	-15,892.59%	-15,599.33%	-	-	-	-	-	-	-	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%
Net Income Growth (1Y)	201.29%	275.96%	297.79%	135.95%	40.12%	15.65%	4.88%	-14.51%	4.62%	-12.07%	-20.97%	-29.33%
EPS Growth (1Y)	50.80%	-91.20%	-90.69%	-89.05%	-93.50%	15.53%	3.03%	-14.69%	4.28%	-17.68%	-34.46%	-42.43%
Valuation Metrics
P/E TTM	-3.03	-3.13	-2.12	-2.15	-4.09	-0.31	-0.42	-0.34	-0.46	-5.19	-4.05	-2.54
P/B TTM	3.06	2.75	1.61	1.42	1.61	-0.45	-1.04	0.96	0.90	6.69	3.89	2.07
P/S TTM	480.86	487.48	-	-	-	-	-	-	-	-	-	-
Market Cap	499.61M	506.50M	326.82M	165.18M	224.23M	13.55M	16.12M	10.96M	18.06M	193.37M	149.49M	96.52M
Enterprise Value	327.91M	317.23M	113.52M	31.81M	71.47M	-8.88M	18.84M	10.96M	-4.33M	162.09M	107.70M	47.12M
Calculated Values
Free Cash Flow TTM	-73.62M	-70.68M	-72.45M	-51.79M	-14.27M	-6.63M	-6.30M	-7.64M	-35.73M	-33.81M	-34.90M	-35.20M
Net Debt	-171.70M	-189.27M	-213.30M	-133.37M	-152.75M	-22.43M	2.72M	0.00	-22.39M	-31.28M	-41.79M	-49.41M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-22Sale

Owner: Pinkas, Jan

Title: Chief Scientific Officer

Shares: 1,288

Price/Share: $17.99

Value: $23,171.12

Shares Owned: 22,239

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Im, Ellie Eunkyung

Title: Chief Medical Officer

Shares: 1,219

Price/Share: $17.99

Value: $21,929.81

Shares Owned: 22,069

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Bispham, Barbara Harlin

Title: See Remarks

Shares: 1,218

Price/Share: $17.99

Value: $21,911.82

Shares Owned: 19,330

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Lynch, Ryan

Title: See Remarks

Shares: 465

Price/Share: $17.99

Value: $8,365.35

Shares Owned: 13,871

Relationship: Officer

Ownership: Direct

2026-06-22Sale

Owner: Scalzo, Richard William

Title: Chief Financial Officer

Shares: 1,112

Price/Share: $17.99

Value: $20,004.88

Shares Owned: 20,298

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-22	Pinkas, Jan	Officer	Chief Scientific Officer	Direct	Sale	1,288	17.99	$23,171.12	22,239	4
2026-06-22	Im, Ellie Eunkyung	Officer	Chief Medical Officer	Direct	Sale	1,219	17.99	$21,929.81	22,069	4
2026-06-22	Bispham, Barbara Harlin	Officer	See Remarks	Direct	Sale	1,218	17.99	$21,911.82	19,330	4
2026-06-22	Lynch, Ryan	Officer	See Remarks	Direct	Sale	465	17.99	$8,365.35	13,871	4
2026-06-22	Scalzo, Richard William	Officer	Chief Financial Officer	Direct	Sale	1,112	17.99	$20,004.88	20,298	4
2026-06-22	Mcneill, Jonathan	Officer	President and COO	Direct	Sale	20,549	17.99	$369,676.51	139,158	4
2026-06-22	Brumm, Joshua T	Director,Officer	Chief Executive Officer	Direct	Sale	42,305	17.99	$761,066.95	281,212	4
2025-12-04	Harwin, Peter Evan, Fairm…	Director,TenPercentOwner	-	Indirect	Purchase	1,360,000	13.41	$18,237,600.00	2,747,866	4
2024-08-08	Siren,, L.L.C., Debbane R…	TenPercentOwner	-	Direct	Sale	260,873	0.19	$49,565.87	6,317,565	4
2024-08-06	Invus, Public Equities Ad…	TenPercentOwner	-	Direct	Sale	55,732	0.18	$10,031.76	6,639,926	4
2024-08-02	Siren,, L.L.C., Invus Glo…	TenPercentOwner	-	Direct	Sale	286,200	0.20	$57,240.00	6,860,181	4
2024-07-30	Siren,, L.L.C., Invus Glo…	TenPercentOwner	-	Direct	Sale	756,835	0.22	$166,503.70	7,209,945	4
2024-06-21	Rock, Edwin	Officer	Chief Medical Officer	Direct	Purchase	115,000	0.27	$31,050.00	680,403	4
2024-06-18	Hahn, Brian M.	Officer	SVP Finance, CFO	Direct	Purchase	17,500	0.25	$4,375.00	70,643	4
2023-09-22	Rock, Edwin	Officer	Chief Medical Officer	Direct	Purchase	30,403	1.38	$41,956.14	375,403	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

89.79%

Inst. Shares: 24,755,630

Shares Outstanding: 27,571,935

2025-12-31

84.88%

Inst. Shares: 23,390,941

Shares Outstanding: 27,556,767

2025-09-30

78.72%

Inst. Shares: 10,935,654

Shares Outstanding: 13,892,516

2025-06-30

Inst. Shares: 10,751,454

Shares Outstanding: 645,223

2025-03-31

Inst. Shares: 30,694,313

Shares Outstanding: 645,223

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	24,755,630	27,571,935	89.79%
2025-12-31	23,390,941	27,556,767	84.88%
2025-09-30	10,935,654	13,892,516	78.72%
2025-06-30	10,751,454	645,223	-
2025-03-31	30,694,313	645,223	-
2024-12-31	30,349,512	644,772	-
2024-09-30	17,295,260	644,840	-
2024-06-30	24,977,854	644,838	-
2024-03-31	36,056,228	644,572	-
2023-12-31	25,453,121	633,425	-
2023-09-30	24,998,358	643,497	-
2023-06-30	25,718,191	642,762	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CRESCENT BIOPHARMA, INC. (CBIO) — SEC Financial Statements & Analysis

CRESCENT BIOPHARMA, INC. (CBIO) is a pharmaceutical preparations company, incorporated in E9. CRESCENT BIOPHARMA, INC. trades on Nasdaq as: CBIO. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CRESCENT BIOPHARMA, INC. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.12x, a Price-to-Sales (P/S) ratio of 480.86x (TTM), a Price-to-Book (P/B) ratio of 3.06x (TTM), at a market cap of $499.61M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.12x
P/S TTM: 480.86x
P/B TTM: 3.06x
Market Cap: $499.61M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CRESCENT BIOPHARMA, INC. in?

CRESCENT BIOPHARMA, INC. (CBIO) operates in the Pharmaceutical Preparations industry.

What is CBIO's market cap?

CRESCENT BIOPHARMA, INC. (CBIO) has a market capitalization of $499.61M as of 2026-06-30.

What exchange does CBIO trade on?

CRESCENT BIOPHARMA, INC. (CBIO) trades on the Nasdaq.

Where is CRESCENT BIOPHARMA, INC. incorporated?

CRESCENT BIOPHARMA, INC. is incorporated in Cayman Islands.